November 4, 2026
FDA to review uniQure’s BLA for Huntington’s gene therapy
The US Food and Drug Administration (FDA) has accepted a biologics licence application (BLA) under its accelerated approval pathway from uniQure for ifezuntirgene inilparvovec, an investigational gene therapy to treat Huntington’s disease.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







